Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Oct 10, 2019--
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Oct 10, 2019--